Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephen Barlas

Showing results (71-80 of 149) with videos related to

Pageof 15
Sort By:
P & T : a Peer-Reviewed Journal for Formulary Management|January 29, 2015
Hospitals Can Collect Leftover Narcotics: But Restrictions Imposed by the DEA Are a DisincentiveStephen Barlas
P & T : a Peer-Reviewed Journal for Formulary Management|October 16, 2012
Pharmacists Welcome FDA's Opioids REMS: How Directly Will They Be Affected?Stephen Barlas
P & T : a Peer-Reviewed Journal for Formulary Management|June 3, 2014
DEA Proposal on Hydrocodone Combination Products Divides Pharmacists: The Impacts on Pharmacy Workload and Prescription Drug Abuse Are at IssueStephen Barlas
P & T : a Peer-Reviewed Journal for Formulary Management|March 24, 2015
FDA Advisory Committee Approval of First Biosimilar Leaves Questions Unanswered: Sandoz's Filgrastim Faces Naming and Court HurdlesStephen Barlas
P & T : a Peer-Reviewed Journal for Formulary Management|August 10, 2016
Congress and Federal Agencies Address Opioid Abuse Epidemic, But Will New Initiatives Be Successful?Stephen Barlas
P & T : a Peer-Reviewed Journal for Formulary Management|June 6, 2015
Pharmacists Step Up Efforts to Combat Opioid Abuse: The CDC and Congress Are Trying to Pitch InStephen Barlas
P & T : a Peer-Reviewed Journal for Formulary Management|March 2, 2018
NIH Starts to Spend $4.8 Billion in "Extra" Cures Drug Research MoneyStephen Barlas
P & T : a Peer-Reviewed Journal for Formulary Management|March 2, 2018
The 21st Century Cures Act: FDA Implementation One Year Later: Some Action, Some Results, Some QuestionsStephen Barlas
P & T : a Peer-Reviewed Journal for Formulary Management|February 2, 2018
Talk of a "Default" Drug Formulary Rattles Industry: CMS Could Move in That Direction for Marketplace Plans After 2019, but the Discussion Has Already StartedStephen Barlas
P & T : a Peer-Reviewed Journal for Formulary Management|January 15, 2016
Conflicting Opinions Flood FDA on Its Proposal for Biosimilar NamingStephen Barlas
Pageof 15

Showing results (71-80 of 149) with videos related to

Sort By:
Pageof 15
P & T : a Peer-Reviewed Journal for Formulary Management|January 29, 2015
Hospitals Can Collect Leftover Narcotics: But Restrictions Imposed by the DEA Are a DisincentiveStephen Barlas
P & T : a Peer-Reviewed Journal for Formulary Management|October 16, 2012
Pharmacists Welcome FDA's Opioids REMS: How Directly Will They Be Affected?Stephen Barlas
P & T : a Peer-Reviewed Journal for Formulary Management|June 3, 2014
DEA Proposal on Hydrocodone Combination Products Divides Pharmacists: The Impacts on Pharmacy Workload and Prescription Drug Abuse Are at IssueStephen Barlas
P & T : a Peer-Reviewed Journal for Formulary Management|March 24, 2015
FDA Advisory Committee Approval of First Biosimilar Leaves Questions Unanswered: Sandoz's Filgrastim Faces Naming and Court HurdlesStephen Barlas
P & T : a Peer-Reviewed Journal for Formulary Management|August 10, 2016
Congress and Federal Agencies Address Opioid Abuse Epidemic, But Will New Initiatives Be Successful?Stephen Barlas
P & T : a Peer-Reviewed Journal for Formulary Management|June 6, 2015
Pharmacists Step Up Efforts to Combat Opioid Abuse: The CDC and Congress Are Trying to Pitch InStephen Barlas
P & T : a Peer-Reviewed Journal for Formulary Management|March 2, 2018
NIH Starts to Spend $4.8 Billion in "Extra" Cures Drug Research MoneyStephen Barlas
P & T : a Peer-Reviewed Journal for Formulary Management|March 2, 2018
The 21st Century Cures Act: FDA Implementation One Year Later: Some Action, Some Results, Some QuestionsStephen Barlas
P & T : a Peer-Reviewed Journal for Formulary Management|February 2, 2018
Talk of a "Default" Drug Formulary Rattles Industry: CMS Could Move in That Direction for Marketplace Plans After 2019, but the Discussion Has Already StartedStephen Barlas
P & T : a Peer-Reviewed Journal for Formulary Management|January 15, 2016
Conflicting Opinions Flood FDA on Its Proposal for Biosimilar NamingStephen Barlas
Pageof 15